Tinubu Square Reaches Top 5 of Corda InsurTech Challenge and Demonstrates a Unique Breakthrough Solution for Surety Industry Players
Tinubu Square, a leading provider of credit insurance, surety and trade finance solutions, has reached the final “top 5” of the inaugural Global Corda InsurTech Challenge, a competition that rewards blockchain insurance startups and the innovation investment arms of insurance companies.
Organised by R3, the enterprise blockchain software developer with an ecosystem of more than 300 participants across multiple industries, the challenge invites organisations to share their Insurance CorDapps, the applications that will work on Corda, its open-source blockchain platform.
Tinubu Square has progressed through a number of different rounds, initially competing against more than 60 companies. The entrants were asked to design a CorDapp that could be used to solve a unique insurance business challenge.
Through various activities, including building a business case, developing a roadmap and presenting a live demo of the CorDapp, the entrants were shortlisted down until the final five were selected. Tinubu Square is the only European company to reach the top 5 selected companies and has been recognized with an ‘honorable mention’. The contestants will move on to the final presentations and the announcement of the winner will take place at the CordaCon event in London on October 23rd and 24th.
“The CORDA InsurTech Challenge has been a stimulating and often demanding test for the Tinubu Innovation LAB,” commented Jérôme Pezé, CEO and founder of Tinubu Square. “The LAB was created to deliver the potential benefits of technology innovation, such as blockchain, data analytics & AI to the credit and surety insurance industry. We are proud to have reached this stage of the award process which recognizes the breakthrough we have developed. Indeed we have moved a major step forward in the implementation of blockchain for trade transactions and for credit & surety insurers to contribute to this evolution. Our solution enables credit & surety insurers to guarantee a contract and process the transaction using DLT/Blockchain. The solution allows the contractor, the owner, the lead insurer and its risk distribution partners (co-insurers, reinsurers, banks, etc) to manage the issuance, validation and monitoring of the guarantee life cycle through a common blockchain solution and therefore create a shared auditable distributed ledger. We are looking forward to collaborating further with the R3 ecosystem.”
More information about the CORDA InsureTech Challenge is at https://www.r3.com/insurtech-challenge/
About Tinubu Square
Founded in 2000, Tinubu Square is a software vendor, enabler of the Credit Insurance, Surety and Trade Finance digital transformation. Tinubu Square enables organizations across the world to significantly reduce their exposure to risk and their financial, operational and technical costs with best-in-class technology solutions and services. Tinubu Square provides SaaS solutions and services to different businesses including credit insurers, receivables financing organizations and multinational corporations. Tinubu Square has built an ecosystem of customers in over 20 countries worldwide and has a global presence with offices in Paris, London, New York, Montreal and Singapore. For more information: www.tinubu.com
Julie Kirby – Ascendant
Phone: +44 (0) 7956 955625
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Metanoia Announces Its Next Generation Broadband Access Technology14.10.2019 07:11:00 CEST | Press release
BROADBAND WORLD FORUM 2019--In order to respond to the ever increasing demand for higher data rate of xDSL over copper, coax lines, Metanoia Communications (“Metanoia”) announced today the launch of its latest family of chipsets that supports all the ITU-T Gfast (212MHz profile) and VDSL2 (35MHz profile) standards and builds on Metanoia’s proven Gfast, VDSL2 and ADSL2/2+ technology. With its MT-x2331 product family, Metanoia will deliver the industry first next generation broadband access xDSL PHY chipset for multiple applications including home gateways, low density xDSL Central Office systems and standalone xDSL termination, such as SFP modules. Emerging trends in the Broadband Access Networks make the use of standalone xDSL PHY solution more pertinent for WAN PHY agnostic platforms. A standalone xDSL PHY enables cost-effective upgrade of existing WAN deployments, an approach which is increasingly attractive to Operators. Metanoia MT-x2331 series is a chipset family that supports all
BIZCENTER USA Launches Coworking Facility in Orlando With Plans for Nationwide Franchise14.10.2019 04:01:00 CEST | Press release
Multimedia, Inc. (www.multimediausa.com) starts today the operations of BIZCENTER USA LLC, its affiliate for shared workspaces and virtual offices. Located on a fully owned 4,400 sq. ft. area in one of the most strategic regions of Orlando, Florida, BIZCENTER USA is offering brand-new state of the art executive suites in a facility with upscale conference rooms, reception, luxury lounge, and kitchen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191013005018/en/ Founded in Orlando in 1991, Multimedia is a leading marketing and communications company, highly recognized worldwide for its professional integrity, serving advertising agencies, direct clients and media outlets across all continents. According to Fernando Mariano, president of both companies, the creation of BIZCENTER USA fulfills the needs for a stylish shared workspace and virtual office facility in Southwest Orlando. “Multimedia has strong ties with the Orlando
Vodafone Idea and Mavenir Partner to Extend Network as a Platform14.10.2019 01:00:00 CEST | Press release
Mavenir, the industry's only end-to-end cloud-native 4G and 5G network software provider for CSPs today announced the extension of its partnership with Vodafone Idea Limited (VIL), India’s leading telecom operator, to extend VIL Network as a Platform, reaching distributed presence across all the major Industrial, Commercial, and Services clusters in India. This partnership will focus on three thrust areas. First, building a universal secured Cloud capable of hosting multiple tenants and third-party applications. Second, building a fully automated platform that enables self-provisioning of various workloads. Third and most importantly, setting up a joint innovation lab and team that will consistently innovate on Chipset, Operating System, and work at Application level to offer unique APIs and enable new use cases and delightful experience to VIL customers. “Vodafone Idea has the largest Edge Cloud deployment in India. Our partnership with Mavenir will enable continued innovation in opti
SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference12.10.2019 04:00:00 CEST | Press release
SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise. The company’s Therapeutics division will initially focus on the development and commercialization of lutetium‑177, or Lu‑177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu‑177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells. The first Lu‑177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properti
Smart Taxation – A Step Towards a Fair, Efficient and Growth-Friendly European Taxation Approach11.10.2019 22:01:00 CEST | Press release
In a rapidly changing global economy, smart taxation is essential to drive growth and economic prosperity. However, the European Union (EU) continues to fall behind as it persists with a one-size-fits all taxation system. This year’s GLOBSEC Tatra Summit hosts a Focus Group, bringing together international experts, looking to reshape and support a smarter European tax policy. Europe is at a crossroads in adapting its tax policy to the realities of today’s global economy. The EU plays a key role in overseeing national tax rules in some areas - particularly in relation to EU business and consumer policies. The institutional changeover marks a perfect opportunity for the Tatra Summit to place major topics on the radar of decision-makers and offer efficient recommendations. So now is the time to adapt the EU’s taxation model to be fit-for-purpose. With member states around the table, European fiscal authorities should design a model that does not have a disruptive impact on national needs
Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund11.10.2019 13:19:00 CEST | Press release
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement. "Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer. “It is vital that the exp